FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Wolverine Stack

Recovery & Healingbeginner

92

상호작용

92
Share
펩타이드

2

일 평균 mcg

3,000

수준

beginner

추가됨

May 17, 2026

개요

The Wolverine Stack combines two of the most well-researched regenerative peptides in the biohacking community: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. It operates through multiple mechanisms including upregulation of growth factor receptors (VEGF, FGF, EGF), modulation of the nitric oxide system, and promotion of angiogenesis — the formation of new blood vessels at injury sites. In animal models, BPC-157 has demonstrated remarkable ability to accelerate healing of tendons, ligaments, muscles, and even bone. TB-500 is the active region of Thymosin Beta-4, a 43-amino-acid protein naturally present in nearly all human cells. It functions primarily by sequestering G-actin, which promotes cellular migration to wound sites, and by upregulating actin polymerization — essential for cellular repair and tissue remodeling. TB-500 also reduces inflammation by decreasing pro-inflammatory cytokines and promotes stem cell maturation and differentiation. The synergy between these two peptides is substantial. BPC-157 creates new vascular pathways to the injury site while TB-500 facilitates cellular migration along those pathways. BPC-157 provides local tissue-specific repair signaling while TB-500 offers systemic anti-inflammatory and repair activation. Together, they cover both the vascular supply and the cellular machinery needed for complete tissue regeneration. This combination is favored by athletes and individuals recovering from soft-tissue injuries, with many reporting noticeable improvement within 1-2 weeks of initiation.

용량 프로토콜

BPC-157

Twice per day· subcutaneous

BPC-157에 대한 자세한 내용 →

250 mcg

1회 용량당

TB-500

2x/week· subcutaneous

TB-500에 대한 자세한 내용 →

2,500 mcg

1회 용량당

목표 및 증거

Injury recoveryTissue repairTendon healingMuscle recoveryJoint repair
증거 등급:동물 연구

경고

  • BPC-157 and TB-500 were removed from the FDA Category 2 list (April 2026) but remain under PCAC review (July 23, 2026) — removal is not approval; neither is legal to compound yet.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.